IL311234A - Novel combinations of antibodies and uses thereof - Google Patents

Novel combinations of antibodies and uses thereof

Info

Publication number
IL311234A
IL311234A IL311234A IL31123424A IL311234A IL 311234 A IL311234 A IL 311234A IL 311234 A IL311234 A IL 311234A IL 31123424 A IL31123424 A IL 31123424A IL 311234 A IL311234 A IL 311234A
Authority
IL
Israel
Prior art keywords
antibodies
new combinations
combinations
new
Prior art date
Application number
IL311234A
Other languages
English (en)
Hebrew (he)
Inventor
Bj?Rn Frend?Us
Matilda Rehn
Monika Semmrich
Linda M?Rtensson
Jean-Baptiste Marchand
Original Assignee
Bioinvent Int Ab
Transgene Sa
Bj?Rn Frend?Us
Matilda Rehn
Monika Semmrich
Linda M?Rtensson
Marchand Jean Baptiste
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioinvent Int Ab, Transgene Sa, Bj?Rn Frend?Us, Matilda Rehn, Monika Semmrich, Linda M?Rtensson, Marchand Jean Baptiste filed Critical Bioinvent Int Ab
Publication of IL311234A publication Critical patent/IL311234A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL311234A 2021-09-22 2022-09-21 Novel combinations of antibodies and uses thereof IL311234A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21306310 2021-09-22
EP22305050 2022-01-18
PCT/EP2022/076268 WO2023046777A1 (en) 2021-09-22 2022-09-21 Novel combinations of antibodies and uses thereof

Publications (1)

Publication Number Publication Date
IL311234A true IL311234A (en) 2024-05-01

Family

ID=83507478

Family Applications (1)

Application Number Title Priority Date Filing Date
IL311234A IL311234A (en) 2021-09-22 2022-09-21 Novel combinations of antibodies and uses thereof

Country Status (10)

Country Link
US (1) US20240374719A1 (enExample)
EP (1) EP4405050A1 (enExample)
JP (1) JP2024534550A (enExample)
KR (1) KR20240067076A (enExample)
AU (1) AU2022351060A1 (enExample)
CA (1) CA3231396A1 (enExample)
IL (1) IL311234A (enExample)
MX (1) MX2024003578A (enExample)
TW (1) TW202321458A (enExample)
WO (1) WO2023046777A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10765710B2 (en) * 2014-07-16 2020-09-08 Institut Gustave-Roussy Combination of oncolytic virus with immune checkpoint modulators
CN120648657A (zh) * 2024-03-08 2025-09-16 上海锦斯生物技术有限公司 一种修饰的溶瘤病毒及其组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
ES2611975T3 (es) 2006-06-20 2017-05-11 Transgene S.A. Procedimiento para producir poxvirus y composiciones de poxvirus
EP1985305A1 (en) 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
US8012738B2 (en) 2007-05-14 2011-09-06 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
BRPI0820576B1 (pt) 2007-11-19 2021-10-19 Transgène S.A. Uso de um poxvírus oncolítico compreendendo um gene i4l e/ou f4l defectivo ou uma composição compreendendo o mesmo
EP2240573A4 (en) 2008-02-12 2011-08-31 Sanofi Pasteur Ltd METHODS OF USING ION EXCHANGE CHROMATOGRAPHY AND DIFFUSION EXCLUSION CHROMATOGRAPHY FOR PURIFYING POXVIRUS
NZ596595A (en) 2009-05-12 2013-05-31 Transgene Sa Method for orthopoxvirus production and purification
ES2813413T3 (es) 2011-08-05 2021-03-23 Sillajen Biotherapeutics Inc Métodos y composiciones para la producción de virus vaccina
MX2019010797A (es) * 2017-03-15 2019-10-24 Amgen Inc Uso de virus oncoliticos, solos o en combinacion con un inhibidor de punto de control, para el tratamiento del cancer.
AU2018254626B2 (en) * 2017-04-21 2023-12-21 Sillajen, Inc. Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
KR20200131863A (ko) * 2018-03-13 2020-11-24 메모리얼 슬로안 케터링 캔서 센터 암 면역요법을 위한, 면역 관문 차단을 발현하는 종양용해 백시니아 바이러스
EP3617230A1 (en) * 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
TW202102543A (zh) * 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途
CN111763660A (zh) * 2020-08-07 2020-10-13 南京大学 一种重组溶瘤痘苗病毒及其制备方法和应用

Also Published As

Publication number Publication date
EP4405050A1 (en) 2024-07-31
MX2024003578A (es) 2024-04-03
WO2023046777A1 (en) 2023-03-30
WO2023046777A8 (en) 2023-05-11
KR20240067076A (ko) 2024-05-16
AU2022351060A1 (en) 2024-04-11
JP2024534550A (ja) 2024-09-20
US20240374719A1 (en) 2024-11-14
TW202321458A (zh) 2023-06-01
CA3231396A1 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
EP4089115A4 (en) Anti-tigit antibodies and usage method
EP4472967A4 (en) Iraqi Degradation Agents and Their Uses
EP4499707A4 (en) CCR8 ANTIBODIES AND THEIR USES
IL285401A (en) Anti-clec2d antibodies and methods of use thereof
PL3601358T3 (pl) Przeciwciała anty-trem2 i sposoby ich wykorzystania
IL287116A (en) Tricyclic degraders of ikaros and aiolos
IL270214A (en) Anti-sortilin antibodies and methods of use thereof
IL290233A (en) Antigen-binding protein constructs and uses thereof
IL287039A (en) Cd19 antibodies and methods of using the same
EP4499068A4 (en) Iraqi Degradation Agents and Their Uses
IL286641A (en) Engineered iga antibodies and methods of use
EP4142793A4 (en) ABCB5-SPECIFIC ANTIBODIES AND THEIR USES
EP4126938A4 (en) ANTIBODIES BINDING TO SIGLEC15 AND THEIR USES
EP4458851A4 (en) Anti-GPRC5D Antibodies and Their Use
IL311301A (en) Anti-siglec-6 antibodies and methods of use thereof
EP4244255A4 (en) ANTI-TIGIT ANTIBODIES AND THEIR USES
EP4132569A4 (en) ANTI-PHF-TAU ANTIBODIES AND USES
EP4458854A4 (en) GPRC5D ANTIBODY AND ITS USE
EP4247419A4 (en) ANTI-MARCO ANTIBODIES AND RELATED USES
IL283136A (en) Antibodies to mucin-16 and methods of use thereof
EP4396224A4 (en) Anti-DLL3 Antibodies and Their Uses
EP4393954A4 (en) Monoclonal Anti-TNFR2 Antibody and its Application
EP4146272A4 (en) ANTI-COVID-19 ANTIBODIES AND THEIR USES
EP4437002A4 (en) ANTI-HSP90 ANTIBODY? AND ITS USES
KR20240101546A9 (ko) 항-글리코-lamp1 항체 및 그의 용도